Shengshi Taikang Honored as a "Pioneer Enterprise for Independent Innovation in China's Pharmaceutical Industry"

Recently, at the "15th China Pharmaceutical Industry Development Summit Forum," hosted by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce, the "2022-2023 China Pharmaceutical Industry Most Influential List" was unveiled, featuring among others: Shengshi Taikang awarded the honor of "China's Pioneering Enterprise for Independent Innovation in the Pharmaceutical Industry" 。

"The Most Influential List in China's Pharmaceutical Industry" was compiled by a selection panel assembled from top domestic experts, invited by the All-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce, in collaboration with several renowned media outlets across the country. Recognized as a key indicator of China's pharmaceutical industry trends, this list is designed to help award-winning companies maximize their influence and amplify their impactful voices.

The "Pioneering Chinese Companies in Independent Innovation for the Pharmaceutical Industry" list places greater emphasis on a company's ability to innovate independently. Leading domestic innovative drug firms such as Hengrui, CSPC, Zhengda Tianqing, and BeiGene were all selected for the list. Shengshi Taikang stood out among China's many cutting-edge pharmaceutical companies to earn this prestigious recognition. Thanks to the company's independently developed, innovative drugs—several of which have already advanced into clinical stages—the flagship product, a new glucose-lowering medication named "Shengglitine" (literally "Ten Years Sharpening One Sword"), which has been years in the making, is poised to enter commercialization. 。

As a next-generation, highly selective DPP-4 inhibitor independently developed by Shengshi Taikang, Phase III clinical results for senglitazone demonstrate unique advantages such as high selectivity, potent inhibitory activity, low dosing, and enhanced safety, positioning it as a potential best-in-class glucose-lowering therapy. At the 2023 Peking University Diabetes Forum held this May, Professor Ji Linong, Director of the Department of Endocrinology at Peking University People's Hospital, unveiled the data and results from two Phase III clinical trials of sotagliflozin. In his concluding clinical summary, he emphasized that sotagliflozin demonstrates excellent efficacy and safety profiles, expressing hope that it will soon become available as a superior treatment option for clinicians managing diabetes patients.

As DPP-4 inhibitors gain increasing popularity in China, the market size for these drugs (all of which are imported) reached nearly 10 billion RMB in 2022. Combination therapy is an important approach in diabetes treatment, with sotagliflozin being compatible with most mainstream antidiabetic drugs—such as metformin and SGLT-2 inhibitors—allowing patients to benefit from the unique advantages of each class while minimizing the risk of additional side effects. Therefore, according to the Sullivan Research Report: By 2030, liraglutide-based drugs in China are expected to surpass A market size of 30 billion The future looks promising.

Dr. Yu Qiang, Founder and CEO of Shengshi Taike, stated: "Being recognized as a pioneering enterprise in China's pharmaceutical industry for independent innovation is a tremendous honor and a significant boost for us. Currently, the company is diligently preparing for the commercialization of our core innovative product, Shengetlin. At the same time, we’ve initiated the final round of pre-IPO financing ahead of our planned listing on the STAR Market, further accelerating the industrialization and commercialization of Shengetlin. We sincerely hope this groundbreaking drug will soon reach the market, bringing much-needed relief to China’s vast population of diabetes patients."